Should I use compounded hormones or stick to FDA approved products in my practice?

Default to FDA approved products, and treat compounding as a documented exception with a stated clinical reason. That is the position you can defend in front of a board, an expert reviewer or your own carrier, and it is also the position the available evidence supports. Approved estradiol and micronized progesterone products cover the great majority of what a menopause practice needs, in a wide range of doses and routes, with established potency and a body of trial evidence behind them.

That is not the same as saying compounding is never appropriate. There are real situations, an excipient allergy, a dose no manufacturer makes, a national shortage, where a 503A pharmacy is the right answer and refusing to use one would be poor care. The distinction that matters is whether compounding is your fallback or your business model.

Here is how the two options actually differ, on the dimensions that carry consequences.

The regulatory difference between 503A, 503B, and an approved product

These three categories are often discussed as if they were points on a spectrum of quality. They are not. They are separate legal statuses created by different provisions of federal law.

	FDA approved product	503A compounding pharmacy	503B outsourcing facility
FDA reviews safety and efficacy	Yes, before marketing	No	No
Manufactured under current good manufacturing practice	Yes	No, state pharmacy standards apply	Yes, cGMP required
Requires a patient specific prescription	No	Yes	No, may supply office stock
Primary oversight	FDA	State board of pharmacy	FDA registration and inspection
Adverse event reporting	Required	Limited	Required

The framework comes from the Drug Quality and Security Act of 2013, passed after a contaminated compounded steroid injection caused a national fungal meningitis outbreak. Section 503A covers traditional patient specific compounding, exempt from premarket approval and cGMP but restricted accordingly. Section 503B created outsourcing facilities, which may produce without individual prescriptions but must register with the FDA and comply with cGMP.

The practical takeaway: a 503A preparation has never been evaluated by anyone for whether it works or whether it is consistent from batch to batch. That is not an accusation. It is the definition of the category.

Keep reading: Why do so many menopause patients stop hormone therapy within the first year?

What the National Academies review concluded and what it did not

The National Academies of Sciences, Engineering, and Medicine published a consensus study report on the clinical utility of compounded bioidentical hormone therapy, requested by the FDA. Its central conclusion was that there is insufficient evidence to support the overall clinical utility of compounded bioidentical hormone preparations, and it recommended that use be restricted to patients who cannot use an approved product, for example because of a documented allergy to an ingredient or a need for a dosage form not commercially available.

Two clarifications, because this report is frequently misquoted in both directions.

It did not conclude that compounded hormones are dangerous, or that bioidentical molecules are inferior. Estradiol is estradiol. The report's concern was with the preparation, the lack of evidence, the marketing claims, and the absence of quality oversight, not with the molecule.

It also did not endorse the common marketing framing that compounded preparations are "customized" in a clinically meaningful way. The report was pointed about the use of salivary and serum hormone level testing to titrate doses, which lacks support for guiding menopausal hormone therapy. Symptom response, not a saliva panel, is the accepted basis for titration.

Dose consistency, potency testing, and pellet specific concerns

Approved products are required to demonstrate content uniformity within tight limits, batch after batch. A 503A compounded cream carries no such requirement, and independent testing has repeatedly found compounded hormone preparations that fall outside the labeled potency, in both directions.

Transdermal creams add a second variable on top of the first. Absorption depends on application site, surface area, skin condition and whether the patient washes or exercises afterward. Two sources of variability multiply.

Why pellets deserve their own paragraph

Subcutaneous hormone pellets are the compounded product most likely to generate a complaint, and for structural reasons.

• They are irreversible. If a patient develops an adverse effect, you cannot stop the dose. You can only wait, or surgically retrieve the pellet.
• Testosterone pellet doses commonly used in women often exceed physiologic ranges, and supraphysiologic testosterone produces effects that are not all reversible: voice deepening, hirsutism, clitoromegaly.
• There is no FDA approved testosterone product indicated for women in the United States. Any testosterone you prescribe for a woman is off label, whether compounded or an approved male product dosed down. That is permissible, but it needs to be disclosed and documented.
• The insertion is a procedure. Site infection, extrusion and scarring are real complications with their own consent requirements.

The Menopause Society's position statements have consistently advised against compounded pellets for menopausal symptom management. If you offer them anyway, your documentation burden is substantially higher, not lower.

Keep reading: How should I document a symptom score so it holds up at the next visit?

Liability exposure and how malpractice carriers view compounding

Three exposures stack.

1. Standard of care. An expert reviewer will ask why an approved product was not used. "The patient preferred it" is a weak answer. "She has a documented reaction to the adhesive in every available patch and cannot tolerate oral therapy" is a strong one.
2. Product liability shifts toward you. With an approved product there is a manufacturer with a learned intermediary defense and a full label. With a compounded preparation, the pharmacy and the prescriber are the only parties in the room.
3. Policy language. Some professional liability policies contain exclusions or specific questions about compounded hormone use, pellet insertion, or dispensing from the office. Read your declarations page and your application answers. If you started a pellet program after your last renewal and did not tell your carrier, resolve that before your next patient.

A useful test before you write the script: could you explain this specific prescription, for this specific patient, to a reviewer who has never met either of you, using only what is in the chart? If not, the chart is the problem, not the pharmacy.

When compounding is genuinely justified: allergies, doses, shortages

A short decision rule you can apply at the point of prescribing.

1. Is there an FDA approved product in the route and dose range this patient needs? If yes, prescribe it. Estradiol alone is available as patches across many strengths, gels, sprays, oral tablets, vaginal creams, inserts and rings.
2. If no, is the barrier a documented intolerance to a specific excipient, adhesive or dye? Document the reaction, the products tried, and the date. Then compound.
3. Is the barrier a dose that no approved product provides, and that cannot be reached by splitting, combining or adjusting frequency? Document the calculation. Then compound.
4. Is the barrier a confirmed manufacturer shortage? Document it, and revisit when supply returns.
5. Is the barrier cost or patient preference for a particular concept? Neither is a clinical justification. Address it with counseling, generic options, and a discussion of what the preference is based on.

Note what is absent from that list: hormone level targets derived from saliva or capillary blood testing. Titrating a compounded cream to a serum estradiol number is not an established practice for symptom management, and building a clinical model on it is difficult to defend.

See how PauseNotes handles this for menopause and midlife women's health clinics

Vetting a compounding pharmacy before you send a single script

If you are going to use a 503A pharmacy for the legitimate exceptions above, do the diligence once and keep the file.

• Licensure. Verify the license in your state, not just theirs. Non resident pharmacy permits are required in most states and are checkable online in minutes.
• Inspection and disciplinary history. Board actions are public. Check the home state board and the FDA's published compounding inspection and recall information.
• Accreditation. Pharmacy Compounding Accreditation Board accreditation through ACHC is voluntary and worth asking about. Absence is not disqualifying; presence is meaningful.
• Testing practice. Ask directly: do you perform potency and sterility testing, on what proportion of batches, by which third party laboratory, and will you provide certificates of analysis on request? A pharmacy that hesitates has answered you.
• Sourcing. Ask where the active pharmaceutical ingredient comes from and whether the supplier is FDA registered.
• Marketing conduct. If the pharmacy markets to your patients, offers you training programs bundled with prescribing volume, or proposes any financial arrangement tied to scripts, walk away. That is an anti kickback problem before it is a quality problem.

Explaining the difference to a patient who has already decided

She has usually heard that compounded hormones are natural and approved products are synthetic. The most useful correction is chemical, and it is short: many approved products contain the identical molecule, estradiol or micronized progesterone, that a compounding pharmacy would use. The difference is not the hormone. It is whether anyone has verified that the tube contains what the label says.

Then offer the trade explicitly. "I can give you the same molecule in a product where the dose is guaranteed and I can adjust it precisely, or in one where I am trusting a preparation nobody tested. If the approved version does not work for you, we will compound. Let us start where I can measure the result."

That last clause is the one that closes the conversation, and it is also a promise you have to keep.

Making the measurement real

Every argument in this piece rests on the same foundation: symptom response, tracked over time, is the legitimate basis for hormone therapy titration. Not saliva panels, not pellet schedules, not what the patient remembers about the last three months on the morning of her follow up.

PauseNotes sends structured symptom scores to patients between visits and charts the trend, so your dose decisions are anchored to measured change and your chart shows exactly why you did what you did. If you are choosing an approved product because you can titrate it against real data, make sure you actually have the data.